Cargando…

MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) outbreaks that evolve, from the outset, in a context strictly negative for HIV infection deserve special consideration since they reflect the true intrinsic epidemic potential of the causative strain. To our knowledge, the long-term evolution of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dekhil, Naira, Meftahi, Nedra, Mhenni, Besma, Ben Fraj, Saloua, Haltiti, Raja, Belhaj, Sameh, Mardassi, Helmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849785/
https://www.ncbi.nlm.nih.gov/pubmed/27124599
http://dx.doi.org/10.1371/journal.pone.0153983
_version_ 1782429601334558720
author Dekhil, Naira
Meftahi, Nedra
Mhenni, Besma
Ben Fraj, Saloua
Haltiti, Raja
Belhaj, Sameh
Mardassi, Helmi
author_facet Dekhil, Naira
Meftahi, Nedra
Mhenni, Besma
Ben Fraj, Saloua
Haltiti, Raja
Belhaj, Sameh
Mardassi, Helmi
author_sort Dekhil, Naira
collection PubMed
description BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) outbreaks that evolve, from the outset, in a context strictly negative for HIV infection deserve special consideration since they reflect the true intrinsic epidemic potential of the causative strain. To our knowledge, the long-term evolution of such exceptional outbreaks and the treatment outcomes for the involved patients has never been reported hitherto. Here we provide a thorough description, over an 11-year period, of an MDR-TB outbreak that emerged and expanded in an HIV-negative context, Northern Tunisia. METHODOLOGY/PRINCIPAL FINDINGS: From October 2001 to June 2011, the MDR-TB outbreak involved 48 HIV-negative individuals that are mainly young (mean age 31.09 yrs; 89.6% male) and noninstitutionalized. Drug susceptibility testing coupled to mutational analysis revealed that initial transmission involved an isolate that was simultaneously resistant to isoniazid, rifampicin, ethambutol, and streptomycin. The causative Haarlem3-ST50 outbreak strain expanded mainly as an 11-banded IS6110 RFLP profile (77.1%), from which a 12-banded subclone evolved. After undergoing a 2-year treatment with second-line drugs, 22 (45.8%) patients were cured and 3 (6.2%) completed treatment, thus yielding an overall treatment success rate of 52.1%. Among the patients that experienced unfavorable treatment outcomes, 10 (20.8%) failed treatment, 3 (6.2%) were lost to follow-up, 5 (10.4%) died, and 5 (10.4%) could not be evaluated. Poor adherence to treatment was found to be the main independent predictor of unfavorable outcomes (HR: 9.15; 95% CI 1.72–48.73; P = 0.014). Intriguingly, the evolved 12-banded subclone proved significantly associated with unfavorable outcomes (HR: 4.90; 95% CI 1.04–23.04, P = 0.044). High rate of fatality and relapse was further demonstrated at the long-term, since 70% of those whose treatment failed have died, and 24% among those deemed successfully treated have relapsed. CONCLUSIONS/SIGNIFICANCE: Taken together, the data obtained in this study indicate that MDR-TB clinical isolates could become fit enough to cause large and severe outbreaks in an HIV-negative context. Such MDR-TB outbreaks are characterized by low treatment success rates and could evolve towards increased severity, thus calling for early detection of cases and the necessity to raise the bar of surveillance throughout and beyond the treatment period.
format Online
Article
Text
id pubmed-4849785
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48497852016-05-07 MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years Dekhil, Naira Meftahi, Nedra Mhenni, Besma Ben Fraj, Saloua Haltiti, Raja Belhaj, Sameh Mardassi, Helmi PLoS One Research Article BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) outbreaks that evolve, from the outset, in a context strictly negative for HIV infection deserve special consideration since they reflect the true intrinsic epidemic potential of the causative strain. To our knowledge, the long-term evolution of such exceptional outbreaks and the treatment outcomes for the involved patients has never been reported hitherto. Here we provide a thorough description, over an 11-year period, of an MDR-TB outbreak that emerged and expanded in an HIV-negative context, Northern Tunisia. METHODOLOGY/PRINCIPAL FINDINGS: From October 2001 to June 2011, the MDR-TB outbreak involved 48 HIV-negative individuals that are mainly young (mean age 31.09 yrs; 89.6% male) and noninstitutionalized. Drug susceptibility testing coupled to mutational analysis revealed that initial transmission involved an isolate that was simultaneously resistant to isoniazid, rifampicin, ethambutol, and streptomycin. The causative Haarlem3-ST50 outbreak strain expanded mainly as an 11-banded IS6110 RFLP profile (77.1%), from which a 12-banded subclone evolved. After undergoing a 2-year treatment with second-line drugs, 22 (45.8%) patients were cured and 3 (6.2%) completed treatment, thus yielding an overall treatment success rate of 52.1%. Among the patients that experienced unfavorable treatment outcomes, 10 (20.8%) failed treatment, 3 (6.2%) were lost to follow-up, 5 (10.4%) died, and 5 (10.4%) could not be evaluated. Poor adherence to treatment was found to be the main independent predictor of unfavorable outcomes (HR: 9.15; 95% CI 1.72–48.73; P = 0.014). Intriguingly, the evolved 12-banded subclone proved significantly associated with unfavorable outcomes (HR: 4.90; 95% CI 1.04–23.04, P = 0.044). High rate of fatality and relapse was further demonstrated at the long-term, since 70% of those whose treatment failed have died, and 24% among those deemed successfully treated have relapsed. CONCLUSIONS/SIGNIFICANCE: Taken together, the data obtained in this study indicate that MDR-TB clinical isolates could become fit enough to cause large and severe outbreaks in an HIV-negative context. Such MDR-TB outbreaks are characterized by low treatment success rates and could evolve towards increased severity, thus calling for early detection of cases and the necessity to raise the bar of surveillance throughout and beyond the treatment period. Public Library of Science 2016-04-28 /pmc/articles/PMC4849785/ /pubmed/27124599 http://dx.doi.org/10.1371/journal.pone.0153983 Text en © 2016 Dekhil et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Dekhil, Naira
Meftahi, Nedra
Mhenni, Besma
Ben Fraj, Saloua
Haltiti, Raja
Belhaj, Sameh
Mardassi, Helmi
MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title_full MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title_fullStr MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title_full_unstemmed MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title_short MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
title_sort mdr-tb outbreak among hiv-negative tunisian patients followed during 11 years
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849785/
https://www.ncbi.nlm.nih.gov/pubmed/27124599
http://dx.doi.org/10.1371/journal.pone.0153983
work_keys_str_mv AT dekhilnaira mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT meftahinedra mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT mhennibesma mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT benfrajsaloua mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT haltitiraja mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT belhajsameh mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years
AT mardassihelmi mdrtboutbreakamonghivnegativetunisianpatientsfollowedduring11years